RBRobert L. Brunner

Robert L. Brunner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Robert L. Brunner has a total of 72 co-authors. Here are the top co-authors by number of shared publications:

  • Barbara B. Cochrane

    Family and Child Nursing , University of Washington , Seattle, Washington, USA

    2 shared publications
  • Dorothy Lane

    Department of Preventive Medicine , School of Medicine, State University of New York at Stony Brook , Stony Brook, New York, USA

    2 shared publications
  • Milagros C. Rosal

    Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA, USA

    2 shared publications
  • Aaron Aragaki

    Barnaabei, Brunner, Stefanick, Cochrane, Ockene, Woods. Acquisition of data

    1 shared publication
  • Aaron K. Aragaki

    Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, USA

    1 shared publication
  • Amy E. Millen

    Department of Social and Preventive Medicine , University of Buffalo , Buffalo, New York, USA

    1 shared publication

Latest Publications

  • Barriers to eating are associated with poor physical function in older women

    by Marian L. Neuhouser, Rebecca P. Hunt, Linda Van Horn, James M. Shikany, Marcia L. Stefanick, Karen C. Johnson, Robert Brunner, Brad Cannell, Irene E. Hatsu, Lesley F. Tinker


  • Low-Fat Dietary Pattern Intervention and Health-Related Quality of Life: The Women’s Health Initiative Randomized Controlled Dietary Modification Trial

    by Annlouise R. Assaf, Shirley A.A. Beresford, Patricia Markham Risica, Aaron Aragaki, Robert L. Brunner, Deborah J. Bowen, Michelle Naughton, Milagros C. Rosal, Linda Snetselaar, Nanette Wenger


  • Open Access

    Self-perceived physical health predicts cardiovascular disease incidence and death among postmenopausal women

    by Nazmus Saquib, Robert Brunner, Jessica Kubo, Hilary Tindle, Candyce Kroenke, Manisha Desai, Martha L Daviglus, Norrina Allen, Lisa W Martin, Jennifer Robinson, et al.

    Physical and Mental Component Summary (PCS, MCS, respectively) scales of SF- 36 health-related-quality-of-life have been associated with all-cause and cardiovascular disease (CVD) mortality. Their relationships with CVD incidence are unclear. This study purpose was to test whether PCS and/or MCS were associated with CVD incidence and death. Postmenopausal women (aged 50–79 years) in control groups of the Women’s Health Initiative clinical trials (n = 20,308) completed the SF-36 and standardized questionnaires at trial entry. Health outcomes, assessed semi-annually, were verified with medical records. Cox regressions assessed time to selected outcomes during the trial phase (1993–2005). A total of 1075 incident CVD events, 204 CVD-specific deaths, and 1043 total deaths occurred during the trial phase. Women with low versus high baseline PCS scores had less favorable health profiles at baseline. In multivariable models adjusting for baseline confounders, participants in the lowest PCS quintile (reference = highest quintile) exhibited 1.8 (95%CI: 1.4, 2.3), 4.7 (95%CI: 2.3, 9.4), and 2.1 (95%CI: 1.7, 2.7) times greater risk of CVD incidence, CVD-specific death, and total mortality, respectively, by trial end; whereas, MCS was not significantly associated with CVD incidence or death. Physical health, assessed by self-report of physical functioning, is a strong predictor of CVD incidence and death in postmenopausal women; similar self-assessment of mental health is not. PCS should be evaluated as a screening tool to identify older women at high risk for CVD development and death.


  • The Effect of Calcium plus Vitamin D on Risk for Invasive Cancer: Results of the Women's Health Initiative (WHI) Calcium Plus Vitamin D Randomized Clinical Trial

    by Robert L. Brunner, Jean Wactawski-Wende, Bette J. Caan, Barbara B. Cochrane, Rowan T. Chlebowski, Margery L. S. Gass, Elizabeth T. Jacobs, Andrea Z. LaCroix, Dorothy Lane, Joseph Larson, et al.

    In the Women's Health Initiative (WHI) trial of calcium plus vitamin D (CaD), we examined the treatment effect on incidence and mortality for all invasive cancers. Postmenopausal women (N = 36,282) were randomized to 1,000 mg of elemental calcium with 400 IU vitamin D3 or placebo. Cox models estimated risk of cancer incidence and mortality. After 7.0 yr, 1,306 invasive cancers were diagnosed in the supplement and 1,333 in the placebo group [hazard ratio (HR) = 0.98; CI = 0.90, 1.05, unweighted P = 0.54]. Mortality did not differ between supplement (315, annualized% = .26) and placebo [(347, 0.28%; P = 0.17; HR = 0.90 (0.77, 1.05)]. Significant treatment interactions on incident cancer were found for family history of cancer, personal total intake of vitamin D, smoking, and WHI dietary trial randomized group. Calcium/vitamin D supplementation did not reduce invasive cancer incidence or mortality. Supplementation lowered cancer risk in the WHI healthy diet trial arm and in women without a first-degree relative with cancer. The interactions are only suggestive given multiple testing considerations. The low vitamin D dose provided, limited adherence, and lack of serum 25(OH)D values should be considered when interpreting these findings.


  • Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial

    by Robert L. Brunner, Aaron Aragaki, Vanessa Barnabei, Barbara B. Cochrane, Margery Gass, Susan Do Hendrix, Dorothy Lane, Judith Ockene, Nancy F. Woods, Shagufta Yasmeen, et al.

    Objective: The aim of this study was to assess vasomotor and other menopausal symptoms before starting estrogens or placebo, 1 year later, again at trial closure, and after stopping estrogens or placebo. The role of baseline symptoms and age was examined, as was the frequency and determinants of hormone use and symptom management strategies after discontinuing conjugated equine estrogens (CEE) or placebo. Methods: Intent-to-treat analyses of 10,739 postmenopausal women before and 1 year after randomization to CEE or placebo at 40 clinical centers and a cohort analysis of participants (n = 3,496) who continued taking assigned study pills up to trial closure and completed symptom surveys shortly before (mean, 7.4 ± 1.1 y from baseline) and after (mean, 306 ± 55 d after trial closure) stopping pills were performed. Generalized linear regression modeled vasomotor symptoms, vaginal dryness, breast tenderness, pain/stiffness, and mood swings as a function of treatment assignment and baseline symptoms, before and after stopping study pills. Results: Approximately one third of participants reported at least one moderate to severe symptom at baseline. Fewer symptoms were reported with increasing age, except joint pain/stiffness, which was similar among age groups. At 1 year, hot flashes, night sweats, and vaginal dryness were reduced by CEE, whereas breast tenderness was increased. Breast tenderness was also significantly higher in the CEE group at trial closure. After stopping, vasomotor symptoms were reported by significantly more women who had reported symptoms at baseline, compared with those who had not, and by significantly more participants assigned to CEE (9.8%) versus placebo (3.2%); however, among women with no moderate or severe symptoms at baseline, more than five times as many reported hot flashes after stopping CEE (7.2%) versus placebo (1.5%). Conclusions: CEE significantly reduced vasomotor symptoms and vaginal dryness in women with baseline symptoms but increased breast tenderness. The likelihood of experiencing symptoms was significantly higher after stopping CEE than placebo regardless of baseline symptom status. These potential effects should be considered before initiating CEE to relieve menopausal symptoms.


  • Predictors of Adherence in the Women's Health Initiative Calcium and Vitamin D Trial

    by R. Brunner, J. Dunbar-Jacob, M. S. LeBoff, I. Granek, D. Bowen, L. G. Snetselaar, S. A. Shumaker, J. Ockene, M. Rosal, J. Wactawski-Wende, et al.

    The authors analyzed data from the Women's Health Initiative (WHI) Calcium and Vitamin D Supplementation Trial (CaD) to learn more about factors affecting adherence to clinical trial study pills (b...


  • Calcium, Vitamin D Supplementation, and Physical Function in the Women's Health Initiative

    by Robert L. Brunner, Barbara Cochrane, Rebecca D. Jackson, Joseph Larson, Cora Lewis, Marian Limacher, Milagros Rosal, Sally Shumaker, Robert Wallace